In addition, monogenic FH patients with a PRS score >80th percentile should be considered for more intensive lipid lowering therapy than those with scores <80th percentile (possibly including PCSK9 inhibitors https://www.nice.org.uk/guidance/TA39) to reduce their LDL-C and CVD risk. Here, PCSK9 is linked to familial hyperaldosteronism.